Jan 08, 2023 5:00pm EST

IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S

Dec 20, 2022 12:37pm EST

IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Dec 16, 2022 8:00am EST

IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Dec 15, 2022 7:05am EST

IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL

Dec 13, 2022 7:05am EST

IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split

Dec 07, 2022 4:05pm EST

IMV Shareholders Approve Reverse Stock Split at 88%

Nov 25, 2022 4:05pm EST

IMV Receives Nasdaq Notification Regarding Market Value of Listed Securities

Nov 10, 2022 4:05pm EST

IMV Inc. Announces Third Quarter 2022 Financial and Operational Results

Nov 08, 2022 7:05am EST

IMV Inc. to Announce Third Quarter 2022 Results and Host a Conference Call and Webcast on November 11, 2022

Sep 30, 2022 7:05am EDT

IMV Provides an Update on The VITALIZE Trial